Hartzler Bryan, Carlini Beatriz H, Newville Howard, Crane Heidi M, Eron Joseph J, Geng Elvin H, Mathews W Christopher, Mayer Kenneth H, Moore Richard D, Mugavero Michael J, Napravnik Sonia, Rodriguez Benigno, Donovan Dennis M
a Alcohol & Drug Abuse Institute , University of Washington , Seattle , WA , USA.
b Division of Allergy and Infectious Disease , University of Washington , Seattle , WA , USA.
AIDS Care. 2017 Jul;29(7):846-850. doi: 10.1080/09540121.2016.1271393. Epub 2016 Dec 23.
Increased scientific attention given to cannabis in the United States has particular relevance for its domestic HIV care population, given that evidence exists for both cannabis as a therapeutic agent and cannabis use disorder (CUD) as a barrier to antiretroviral medication adherence. It is critical to identify relative risk for CUD among demographic subgroups of HIV patients, as this will inform detection and intervention efforts. A Center For AIDS Research Network of Integrated Clinical Systems cohort (N = 10,652) of HIV-positive adults linked to care at seven United State sites was examined for this purpose. Based on a patient-report instrument with validated diagnostic threshold for CUD, the prevalence of recent cannabis use and corresponding conditional probabilities for CUD were calculated for the aggregate sample and demographic subgroups. Generalized estimating equations then tested models directly examining patient demographic indices as predictors of CUD, while controlling for history and geography. Conditional probability of CUD among cannabis-using patients was 49%, with the highest conditional probabilities among demographic subgroups of young adults and those with non-specified sexual orientation (67-69%) and the lowest conditional probability among females and those 50+ years of age (42% apiece). Similarly, youthful age and male gender emerged as robust multivariate model predictors of CUD. In the context of increasingly lenient policies for use of cannabis as a therapeutic agent for chronic conditions like HIV/AIDS, current study findings offer needed direction in terms of specifying targeted patient groups in HIV care on whom resources for enhanced surveillance and intervention efforts will be most impactful.
鉴于大麻作为一种治疗药物以及大麻使用障碍(CUD)作为抗逆转录病毒药物依从性障碍的证据都存在,美国对大麻给予的科学关注增加对其国内艾滋病毒护理人群具有特殊意义。确定艾滋病毒患者人口亚组中患CUD的相对风险至关重要,因为这将为检测和干预工作提供信息。为此,对一个由综合临床系统艾滋病研究网络队列(N = 10652)的艾滋病毒阳性成年人组成的样本进行了研究,这些成年人与美国七个地点的护理机构有联系。基于一种具有经过验证的CUD诊断阈值的患者报告工具,计算了总体样本和人口亚组近期大麻使用的患病率以及相应的CUD条件概率。然后,广义估计方程测试了直接将患者人口统计学指标作为CUD预测因素的模型,同时控制了病史和地理位置。使用大麻的患者中CUD的条件概率为49%,其中年轻成年人以及性取向未明确的人群亚组中的条件概率最高(67 - 69%),而女性和50岁及以上人群中的条件概率最低(均为42%)。同样,年轻和男性性别成为CUD的强大多变量模型预测因素。在将大麻用作治疗艾滋病毒/艾滋病等慢性病的治疗药物的政策日益宽松的背景下,当前的研究结果为确定艾滋病毒护理中的目标患者群体提供了必要的指导,在这些群体上加强监测和干预努力的资源将最有成效。